Hormone Insight

Does rosiglitazone increase myocardial infarction or cardiovascular-death risk in type 2 diabetes?

A 2007 meta-analysis found a higher risk of myocardial infarction than control, with a borderline increase in cardiovascular death.

Meta-analysis · New England Journal of Medicine 2007

Reference: Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457-2471.

AI-narrated episode. For healthcare professionals; educational only and not medical advice.

Hormone Insight: https://hormoneinsight.com/

Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Does automated insulin delivery improve glucose control in children under 7 with type 1 diabetes?

A 2026 meta-analysis reported improved time in range and HbA1c compared with standard care over 8 to 16 weeks.

Meta-analysis · Diabetic Medicine 2026

Reference: Lin Q, Zhou Y, Lei M, et al. Diabet Med. 2026;43(7):e70354. doi:10.1111/dme.70354. PMID:42108409. https://pubmed.ncbi.nlm.nih.gov/42108409/

Chapters

0:00 Intro

0:38 The study

3:01 What this means

3:31 Outro

Read the structured trial summary at https://hormoneinsight.com/

AI-narrated. For healthcare professionals; educational only and not medical advice.

Hormone Insight: https://hormoneinsight.com/

Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Does liraglutide reduce hospitalization risk compared with glimepiride in people with type 2 diabetes on metformin?

In GRADE participants with type 2 diabetes on metformin, time to first hospitalization did not differ overall by glucose-lowering drug; liraglutide modestly reduced subsequent hospitalization risk versus glimepiride on assigned treatment.

Secondary analysis of a randomised trial · Diabetes Care 2025

Reference: Hsia DS, Younes N, Ghosh A. Diabetes Care. 2025. PMID: 40424051. https://pubmed.ncbi.nlm.nih.gov/40424051/

AI-narrated episode. For healthcare professionals; educational only and not medical advice.

Hormone Insight: https://hormoneinsight.com/

iPhone/iPad app: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Android app: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Does tirzepatide improve kidney outcomes compared with insulin glargine in type 2 diabetes with high cardiovascular risk?

In people with type 2 diabetes and high cardiovascular risk, tirzepatide slowed eGFR decline and reduced albuminuria more than insulin glargine over a median 85 weeks. This was a secondary analysis of a randomised trial.

Reference: Heerspink HJL, Sattar N, Pavo I, et al. Lancet Diabetes Endocrinol. 2022. PMID: 36152639. https://pubmed.ncbi.nlm.nih.gov/36152639/

AI-narrated episode. For healthcare professionals; educational only and not medical advice.

Hormone Insight: https://hormoneinsight.com/

iPhone/iPad app: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Android app: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Does oral semaglutide reduce major adverse cardiovascular events in high-risk type 2 diabetes patients?

In people with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both, oral semaglutide reduced major adverse cardiovascular events compared with placebo.

Randomized trial · NEJM 2025

Reference: McGuire DK, Marx N, Mulvagh SL. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med. 2025; PMID:40162642.

Chapters

0:00 Intro

0:38 The trial

3:07 My take

3:49 Outro

Read the structured trial summary at https://hormoneinsight.com/

AI-generated narration. This podcast is intended for healthcare professionals and is for educational purposes only; it is not medical advice. Any views expressed are the presenter's own and do not necessarily reflect the views of any institution he works with.

Explore Hormone Insight:

Website: https://hormoneinsight.com/

Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Does weekly subcutaneous semaglutide 2.4 milligrams reduce cardiovascular events in patients with obesity without diabetes?

In patients with established cardiovascular disease and overweight or obesity but without diabetes, once-weekly semaglutide 2.4 mg reduced major adverse cardiovascular events more than placebo.

Randomized trial · NEJM 2023

Reference: Lincoff AM, Brown-Frandsen K, Colhoun HM. N Engl J Med. 2023; PMID:37952131.

Chapters

0:00 Intro

0:38 The trial

3:05 My take

3:42 Outro

Read the structured trial summary at https://hormoneinsight.com/

AI-generated narration. This podcast is intended for healthcare professionals and is for educational purposes only; it is not medical advice. Any views expressed are the presenter's own and do not necessarily reflect the views of any institution he works with.

Explore Hormone Insight:

Website: https://hormoneinsight.com/

Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Does once-weekly 2.4 milligram subcutaneous semaglutide plus lifestyle intervention reduce BMI more than lifestyle intervention alone in adolescents with obesity?

In adolescents with obesity, once-weekly 2.4 mg subcutaneous semaglutide plus lifestyle intervention reduced BMI more than lifestyle intervention alone over 68 weeks, by about 17 percentage points.

Randomized trial · NEJM 2022

Reference: Weghuber D, Barrett T, Barrientos-Pérez M. Once-Weekly Semaglutide in Adolescents with Obesity. N Engl J Med. 2022; PMID:36322838.

Chapters

0:00 Intro

0:38 The trial

3:14 My take

3:43 Outro

Read the structured trial summary at https://hormoneinsight.com/

AI-generated narration. This podcast is intended for healthcare professionals and is for educational purposes only; it is not medical advice. Any views expressed are the presenter's own and do not necessarily reflect the views of any institution he works with.

Explore Hormone Insight:

Website: https://hormoneinsight.com/

Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Can oral orforglipron preserve weight loss after stopping tirzepatide or semaglutide?

In selected adults without diabetes, switching to orforglipron preserved more of their previous injectable-associated weight loss than switching to placebo over 52 weeks; continued injections were not compared.

Randomized trial · Nature Medicine 2026

Reference: Aronne LJ, Horn DB, le Roux CW, et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med. 2026;32(7):2679–2687. First published 13 May 2026. doi:10.1038/s41591-026-04386-7. PMID:42120723. https://pubmed.ncbi.nlm.nih.gov/42120723/

Chapters

0:00 Intro

0:38 The trial

3:31 My take

4:01 Outro

Read the structured trial summary at https://hormoneinsight.com/

AI-generated narration. This podcast is intended for healthcare professionals and is for educational purposes only; it is not medical advice. Any views expressed are the presenter's own and do not necessarily reflect the views of any institution he works with.

Explore Hormone Insight:

Website: https://hormoneinsight.com/

Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Does withdrawal of once-weekly subcutaneous semaglutide 2.4 milligrams lead to weight regain and reversal of cardiometabolic benefits in adults with obesity?

In adults with obesity, stopping semaglutide 2.4 mg led to regain of about two-thirds of lost weight and reversal of most cardiometabolic improvements by one year.

Secondary analysis of RCT · Diabetes Obes Metab 2022

Reference: Wilding JP, Batterham RL, Davies M. Diabetes Obes Metab. 2022; PMID:35441470

Chapters

0:00 Intro

0:38 The trial

3:18 My take

3:46 Outro

Read the structured trial summary at https://hormoneinsight.com/

AI-generated narration. This podcast is intended for healthcare professionals and is for educational purposes only; it is not medical advice. Any views expressed are the presenter's own and do not necessarily reflect the views of any institution he works with.

Explore Hormone Insight:

Website: https://hormoneinsight.com/

Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Does once-weekly tirzepatide reduce body weight in adults with obesity?

In adults with obesity, once-weekly tirzepatide reduced body weight substantially more than placebo over 72 weeks, by up to about 21%.

Randomized trial · NEJM 2022

Reference: Jastreboff AM, Aronne LJ, Ahmad NN. N Engl J Med. 2022; PMID:35658024

Chapters

0:00 Intro

0:38 The trial

3:12 My take

3:48 Outro

Read the structured trial summary at https://hormoneinsight.com/

AI-generated narration. This podcast is intended for healthcare professionals and is for educational purposes only; it is not medical advice. Any views expressed are the presenter's own and do not necessarily reflect the views of any institution he works with.

Explore Hormone Insight:

Website: https://hormoneinsight.com/

Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en